Semus Wealth Partners LLC Cuts Position in Pfizer Inc. (NYSE:PFE)

Semus Wealth Partners LLC decreased its stake in Pfizer Inc. (NYSE:PFE) by 10.2% in the 4th quarter, Holdings Channel reports. The firm owned 11,332 shares of the biopharmaceutical company’s stock after selling 1,283 shares during the quarter. Semus Wealth Partners LLC’s holdings in Pfizer were worth $301,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Convergence Investment Partners LLC lifted its position in shares of Pfizer by 673.9% during the 4th quarter. Convergence Investment Partners LLC now owns 107,413 shares of the biopharmaceutical company’s stock valued at $2,850,000 after acquiring an additional 93,533 shares during the period. Plan Group Financial LLC increased its stake in Pfizer by 14.3% in the 4th quarter. Plan Group Financial LLC now owns 35,789 shares of the biopharmaceutical company’s stock valued at $949,000 after purchasing an additional 4,472 shares in the last quarter. Allied Investment Advisors LLC raised its holdings in Pfizer by 1.4% during the fourth quarter. Allied Investment Advisors LLC now owns 262,737 shares of the biopharmaceutical company’s stock worth $6,970,000 after purchasing an additional 3,534 shares during the last quarter. Bank of Jackson Hole Trust purchased a new stake in Pfizer during the fourth quarter worth $264,000. Finally, Callahan Advisors LLC grew its holdings in Pfizer by 16.5% in the fourth quarter. Callahan Advisors LLC now owns 488,294 shares of the biopharmaceutical company’s stock valued at $12,954,000 after purchasing an additional 69,155 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.1 %

PFE opened at $25.56 on Wednesday. The business has a 50-day moving average of $26.26 and a two-hundred day moving average of $27.46. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a market capitalization of $144.82 billion, a price-to-earnings ratio of 18.12, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter last year, the firm earned $0.10 earnings per share. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.73%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is 121.99%.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Wolfe Research assumed coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, UBS Group dropped their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.